Oncotech Nordic
Tackling the Global Cancer Crisis with Affordable Early Detection
Cancer is one of the world’s most urgent health challenges—responsible for nearly 10 million deaths in 2020, or one in six globally. And the crisis is growing: global cancer diagnoses are projected to reach 35 million by 2050, a 77% increase from 2022, according to the World Health Organization.
Early detection saves lives, but access to effective screening remains uneven, costly, and often unavailable in high-risk regions. Oncotech is developing iris scan technology that may offer a breakthrough: affordable, non-invasive pre-screening that can identify early indicators of the world’s most common cancers—including lung, breast, cervical, uterine, prostate, and colon cancers—using just a single eye image. By scaling this solution, we can empower healthcare systems globally to detect cancer earlier, improve survival rates, and dramatically reduce the cost burden of late-stage treatment.
Portable Pre-Screening
Early detection aims to efficiently identify cancer.
Ophtascan screening technology is the first technology in Europe being clinically tested and validated for on-demand and real-time cancer screening system. Using Lightweight and smartphone-enabled, Ophtascan™ this technology may soon be ready for deployment everywhere—from hospitals in Romania to clinics in Nairobi. Bringing equitable screening to all communities. With minimal equipment and no lab infrastructure, Ophtascan™ can help identify at-risk individuals in real time, enabling targeted intervention, better data collection, and healthier outcomes.
One Image - Instant Insight
A Single Image may provide a World of Health Data. This potentially scalable and affordable pre-screening is being made possible by Oncotech Nordic's Ophtascan™AI-powered screening tool using smartphone-captured iris images to non-invasively detect early-stage cancers (lung, cervical, breast, uterine, prostate) and even type 2 diabetes.
Fast, Affordable & Non Invasive
From Iris to Insight — Health in Seconds
Oncotech Nordic’s AI-powered Ophtascan™ reads subtle patterns in the iris to help detect early signs of cancer, diabetes, and other conditions — all in under 30 seconds. No blood. No biopsy. Just real-time insight, anywhere in the world. Empower your clinicians with earlier insights into oncological and metabolic conditions — improving triage, personalizing care, and optimizing resource allocation.
Streamline Early Detection
Your Iris Holds the Key to Early Detection
Your eyes are more than windows to the soul — they’re gateways to your health. Empower your clinicians with earlier insights into oncological and metabolic conditions — improving triage, personalizing care, and optimizing resource allocation.
Preliminary Market & Readiness Assessment
Ophtascan represents an innovative approach to non-invasive health screening using ocular imaging technology. While the current publicly available data set is limited, the platform addresses a rapidly growing, multi-billion-dollar market for early cancer detection and systemic disease screening through AI-driven diagnostics.
Our preliminary assessment, based solely on public sources, indicates that Ophtascan is at an early stage of clinical and regulatory maturity. The company has achieved CE Class I marking, established initial distribution channels, and generated significant market interest. With additional investment in prospective, multi-site clinical validation, formal regulatory submissions under EU IVDR and FDA pathways, and independent performance verification, Ophtascan has the potential to become a first-mover in ocular-based cancer screening. A structured development plan to address the current documentation and validation gaps could significantly enhance market valuation and partner interest, especially given the growing demand for scalable, non-invasive diagnostics in both developed and emerging markets.
In summary:
- High Market Potential – Novel approach in a large unmet-need category.
- Early-Stage Validation – CE Class I achieved; awaiting formal multi-site clinical data.
- Scalable Technology Platform – Potential to expand indications beyond cancer to other systemic conditions.
- Strategic Opportunity for Investors – Investing at this stage allows the investore to capture upside from completing validation, regulatory approvals, and commercialization.
Partnerships in Early Detection
Join Us in Advancing Early Cancer Detection
Oncotech Nordic is scaling breakthrough iris scan technology that enables affordable, non-invasive pre-screening for the world’s most common cancers. We’re seeking strategic partners to help test and deploy this life-saving innovation across healthcare systems and markets worldwide. If you're ready to invest in accessible diagnostics with global impact—let’s talk.
See For Yourself
Saves Lives, Time, Money and Resources
This technology is portable, intuitive, and designed for global scalability. Whether it's deployed in hospitals, rural clinics, or community health centers, we empower healthcare systems to catch cancer early—when interventions have the greatest impact.